On Monday, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)’s shares surged 5.83% to $12.88, hitting its highest level, as on a biopharmaceutical company, is going to present preclinical and clinical data showcasing its deep oncology pipeline at the 2015 American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia. The presentations describe recent data from Merrimack’s proprietary antibody engineering and nanoliposomal technology platforms, in addition to oral presentations on Phase 1 clinical trials of MM-302 and MM-141.
Preclinical presentations comprise a late breaking abstract on the influence of MM-121, an ErbB3-targeting antibody, on chemosensitivity in heregulin-stimulated tumor cell models, a poster on the mechanism of MM-131, a novel bispecific antibody targeting the c-Met pathway, and a poster on the effect of MM-302 on breast cancer tumor models with intermediate levels of HER2.
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States.
Aeterna Zentaris Inc. (NASDAQ:AEZS)’s shares gained 4.54% to $0.5385, during the last trading session on Monday, after a specialty biopharmaceutical company, declared plans to conduct a new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen™ (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency (“AGHD”), in addition to a dedicated thorough QT study to evaluate the effect of Macrilen™ on myocardial repolarization. This decision follows a positive and helpful meeting with the U.S. Food and Drug Administration (“FDA”) regarding its New Drug Application for Macrilen™. The Company requested the meeting to gain clarity on the approval deficiencies described in the Complete Response Letter (“CRL”) the Company received on November 6, 2014.
Following receipt of the CRL, the Company convened a panel of US and EU endocrinology experts to advise it regarding the options for Macrilen™. The panel advised the Company to continue to seek approval for the compound because of their confidence in its efficacy and because there presently is no FDA-approved diagnostic test for AGHD.
During an end-of-review meeting with the FDA on March 6, 2015 , the Company and the FDA agreed on the general design of the confirmatory study in addition to evaluation criteria. The study will be conducted as a two-way crossover with the insulin tolerance test as the benchmark comparator. The study population will comprise of patients with a medical history documenting risk factors for AGHD and will comprise a spectrum of patients from those with a low risk of having AGHD to those with a high risk of having the condition. The Company will submit a projected final protocol to the FDA for approval preceding to commencing the confirmatory study.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer. It is also developing two oncology compounds, counting an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Quebec City, Canada.
At the end of Monday’s trade, Paramount Gold and Silver Corp. (NYSEMKT:PZG)’s shares gained 4.46% to $1.17, after an exploration stage company, declared that the Securities and Exchange Commission has confirmed effective the Registration Statement on Form S-1 filed by the Company’s partner Paramount Gold Nevada Corp. in connection with the spin-off of Paramount Gold Nevada as a separate, publicly traded company. As formerly declared, Company stockholders of record at the close of business on April 14, 2015 will be entitled to receive one share of ordinary stock of SpinCo for every 20 shares of Paramount ordinary stock held by such stockholder, payable or issuable upon the closing of the formerly declared merger of the Company and Coeur Mining, Inc. (CDE), offered that they continue to hold their Paramount shares at the time of closing of the merger. Cash will be paid in lieu of issuing fractional shares of stock.
Paramount Gold Nevada will have about 8.5 million shares of ordinary stock issued and outstanding when trading is predictable to commence on the NYSE MKT on April 20, 2015 under the ticker “PZG”. The company will be capitalized with about $10 million in cash (less transactional expenses) and no debt.
The merger is anticipated to become effective on April 17, 2015. The merger is subject to the approval of the stockholders of Paramount and Coeur, as applicable, and other customary closing conditions as set forth in the merger contract that was formerly filed under Form 8-K on December 18, 2014, as amended by Amendment No.1 dated as of March 3, 2015. If Paramount stockholders or Coeur stockholders do not approve the merger or if the other conditions to the merger are not satisfied or waived, Paramount will not be required to complete the distribution of SpinCo ordinary stock.
Paramount stockholders of record as of February 24, 2015 have been mailed the Notice of Meeting and Joint Proxy Statement/Prospectus and are entitled to vote on the attainment of Paramount by Coeur and related proposals at the special meeting of the stockholders to be held on April 17, 2015 at 10:00 am EST at The Westin Hotel, 321 North Fort Lauderdale Beach Boulevard, Fort Lauderdale, Florida.
Paramount Gold and Silver Corp., an exploration stage company, attains, explores, and develops gold, silver, and precious metal properties in the United States and Mexico. The company owns a 100% interest in the San Miguel property that comprises 40 mining concessions covering about 142,567 hectares located in southwestern Chihuahua, northern Mexico.
Finally, Micrel Inc. (NASDAQ:MCRL), ended its Monday’s trading session with 4.44% gain, and closed at $15.04, after a leading global manufacturer of IC solutions for the worldwide high performance linear and power, LAN and timing and communications markets, declared that its Board of Directors has approved the postponement of the Company’s 2015 Annual Meeting of Shareholders, from June 19, 2015 to August 4, 2015.
The postponement will allow the Board and the Company’s administration to further evaluate the Company’s planned alternatives. On January 20, 2015, the Company declared that its Board of Directors decided to undertake a comprehensive review of planned alternatives to enhance value for shareholders.
Because of the postponement of the Annual Meeting, the Company has reopened the period for the furnishing of shareholder proposals to be comprised of in the proxy statement under applicable SEC rules, and such period will now expire on April 27, 2015. The deadline for nominations or other proposals under the Company’s bylaws is now June 17, 2015.
The Company’s shareholders of record on June 15, 2015 will be entitled to notice and to vote at the Annual Meeting.
Micrel, Incorporated, together with its auxiliaries, designs, develops, manufactures, and markets analog, mixed-signal, and digital semiconductor devices primarily in North America, Asia, and Europe. It offers power conversion products, counting LDOs, DC/DC converters, analog power switches, PMICs, solid state lighting products, and FET drivers; supervisory and reference products that protect, monitor, and enhance the interface of circuitry around microcontroller and processor circuits; and general linear parts, such as op amps, thermal measurement devices, timers, and other general devices.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
